Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 35Neoplasm Metastasis 32Myelodysplastic Syndromes 18Lung Neoplasms 16Colorectal Neoplasms 14Pancreatic Neoplasms 12Breast Neoplasms 12Multiple Myeloma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Melanoma 9Glioblastoma 9Lymphoma, Follicular 8Carcinoma, Renal Cell 8Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell 7Astrocytoma 7Ovarian Neoplasms 6Glioma 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Lymphoma, T-Cell 5Lymphoma, Mantle-Cell 5Leukemia, Biphenotypic, Acute 5Hematologic Neoplasms 5Stomach Neoplasms 4

Interventions

Docetaxel 6Erlotinib Hydrochloride 5Cetuximab 5Magnetic Resonance Spectroscopy 4Radiotherapy 3Cisplatin 3Biopsy 3Vorinostat 2Trastuzumab 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2SS1(dsFv)PE38 2Radiation 2Paclitaxel 2Immunohistochemistry 2Hydroxyurea 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Everolimus 2Carboplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1talactoferrin alfa 1sargramostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Salivary Gland Neoplasms × Specimen Handling × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡